Johnson & Johnson $JNJ Shares Acquired by 111 Capital

111 Capital grew its position in Johnson & Johnson (NYSE:JNJ) by 94.0% in the second quarter, HoldingsChannel reports. The fund owned 12,474 shares of the company’s stock after acquiring an additional 6,045 shares during the quarter. 111 Capital’s holdings in Johnson & Johnson were worth $1,905,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Highline Wealth Partners LLC lifted its stake in Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after buying an additional 86 shares in the last quarter. Stone House Investment Management LLC purchased a new position in Johnson & Johnson in the 1st quarter valued at about $47,000. 1248 Management LLC purchased a new position in Johnson & Johnson in the 1st quarter valued at about $48,000. von Borstel & Associates Inc. purchased a new position in Johnson & Johnson in the 1st quarter valued at about $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in Johnson & Johnson in the 1st quarter valued at about $52,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 1.4%

Shares of NYSE JNJ opened at $188.51 on Monday. The company has a 50 day simple moving average of $176.18 and a 200-day simple moving average of $162.83. The company has a market capitalization of $453.98 billion, a P/E ratio of 20.16, a P/E/G ratio of 2.40 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $189.78.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business’s revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the firm earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 55.61%.

Wall Street Analyst Weigh In

A number of analysts have commented on JNJ shares. UBS Group set a $198.00 price objective on shares of Johnson & Johnson in a report on Friday. The Goldman Sachs Group increased their price objective on shares of Johnson & Johnson from $185.00 to $186.00 and gave the company a “buy” rating in a report on Friday, September 19th. Barclays increased their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a report on Thursday, July 17th. Citigroup increased their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “buy” rating in a report on Thursday, August 21st. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Johnson & Johnson in a report on Saturday, September 27th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $188.88.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.